Weight Watchers has introduced a new programme designed to help individuals taking GLP-1 medications such as Ozempic or Wegovy maintain their weight loss. The service, called the GLP-1 Success Programme, offers coaching, nutritional guidance and exercise tips to support healthy and sustainable results.
The company said the programme has been created to aid medication tolerance, minimise side effects and protect lean muscle mass. It is structured around how people 'actually live', providing a more flexible and responsive approach to weight management over time.
Dr Kim Boyd, chief medical officer at Weight Watchers, emphasised that GLP-1 medications are not a standalone solution. She noted that while these drugs work across the body, including the brain, to reduce hunger signals and 'food noise', the programme helps translate their biological effects into lasting behaviour change.
The programme includes dose and side-effect tracking, nutrition and movement advice to help preserve muscle, and a community designed specifically for those on a GLP-1 journey. It is set to launch in the UK in January 2026, in partnership with CheqUp, which prescribes GLP-1s in Britain.
Weight Watchers is also rolling out a refreshed brand identity as part of a broader repositioning within the health sector. Chief executive Tara Comonte said members using GLP-1s while engaging with the programme lose more weight and report higher satisfaction and quality of life.
